Worldwide Psychedelic therapeutics market

  • Blog Title
    Blog posted on : 20-10-2021

    Worldwide Psychedelic therapeutics market

    Roots Analysis has done a detailed study on  “Global Psychedelic Therapeutics Market, 2020-2030”, covering key aspects of the industry and identifying potential future growth opportunities

     

     

    To order this 250+ page report, which features 120+ figures and 135+ tables, please visit Global Psychedelic Therapeutics Market, 2020-2030

     

    Key Market Insights

    • Nearly 70 players from across the world presently claim to be engaged in the development and evaluation of therapeutic candidates based on a number of psychedelic compounds, such as ketamine and psilocybin
    • The pipeline features product candidates based on a variety of psychedelic drug classes, which are being investigated for a wide range of target disease indications, and having different routes of administration
    • From a global perspective, this industry is anticipated to evolve significantly over the next few years as federal / regional regulators in different nations are gradually convinced of the clinical significance of this product class
    • Several organizations, having realized the untapped opportunity within this emerging segment of psychedelic therapeutics, have awarded grants of over USD 275 million across 500+ instances between 2015-2020
    • Several trials evaluating various psychedelic compounds against a wide range of therapeutic indication have been registered in the recent past
    • The growing interest is also reflected in the partnership activity since 2017; a number of different types of deals involving various drug classes have been established across multiple geographies
    • Presently, North American companies are actively consolidating their indigenous presence through strategic acquisitions; key value drivers behind such deals include both portfolio and geographical expansion
    • A number of eminent scientists from renowned universities have emerged as key opinion leaders in this domain, owing to their active involvement in clinical development efforts related to interventions based on psychedelics
    • Future market size, based on revenue reported from the sales of marketed and late stage psychedelic-based therapies, is anticipated to be distributed across different therapeutic areas and key geographical regions

     

    For more information, please visit https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html

     

     

    Table of Contents

     

    1.                     PREFACE

    1.1.                   Scope of the Report

    1.2.                   Research Methodology

    1.3.                   Chapter Outlines

     

    2.                     EXECUTIVE SUMMARY

               

    3.                     INTRODUCTION

    3.1.                   Chapter Overview

    3.2.                   History of Psychedelic Substance

    3.3.                   Potential Therapeutic Application of Psychedelic Substance

    3.4.                   Regulation, Toxicity Concerns, Procurement-Related Challenges and Perceptions Regarding Medical Use

    3.5.                   Future Opportunity

     

    4.                     MARKET LANDSCAPE: PSYCHEDELIC THERAPEUTICS

    4.1.                   Chapter Overview

    4.2.                   Psychedelic Therapeutics: Marketed and Development Pipeline

    4.2.1.                Analysis by Phase of Development

    4.2.2.                Analysis by Type of Psychedelic Substance

    4.2.3.                Analysis by Origin of Psychedelic Substance

    4.2.4.                Analysis by Target Therapeutic Area

    4.2.5.                Analysis by Type of Therapy

    4.2.6.                Analysis by Route of Administration

    4.2.7.                Analysis by Dosing Frequency

     

    4.3.                   Psychedelic Therapeutics: List of Developers

    4.3.1.                Analysis by Year of Establishment

    4.3.2.                Analysis by Company Size

    4. 3.3.               Analysis by Location of Headquarters

    4.4.                   Grid Analysis: Distribution by Phase of Development, Origin of Psychedelic Substance and Location of Headquarters

     

    5.                     COMPANY PROFILES

    5.1.                   Chapter Overview

     

    5.2.                   Celon Pharma

    5.2.1.                Company Overview

    5.2.2.                Financial Information

    5.2.3.                Psychedelic Therapeutics Portfolio

    5.2.3.1.             Esketamine DPI

    5.2.4.                Recent Developments and Future Outlook

     

    5.3.                   iX Biopharma

    5.3.1.                Company Overview

    5.3.2.                Financial Information

    5.3.3.                Psychedelic Therapeutics Portfolio

    5.3.3.1.             Wafermine™

    5.3.3.2.             Unnamed (Ketamine)

    5.3.4.                Recent Developments and Future Outlook

               

    5.4.                   MAPS Public Benefit

    5.4.1.                Company Overview

    5.4.2.                Financial Information

    5.4.3.                Psychedelic Therapeutics Portfolio

    5.4.3.1.             Unnamed (MDMA)

    5.4.3.2.             Unnamed (Ibogaine Hydrochloride)

    5.4.3.3.             Unnamed (LSD)

    5.4.3.4.             Unnamed (Ayahuasca)

    5.4.4.                Recent Developments and Future Outlook

     

    5.5.                   MindMed

    5.5.1.                Company Overview

    5.5.2.                Psychedelic Therapeutics Portfolio

    5.5.2.1.             Unnamed (LSD)

    5.5.2.2.             Unnamed (MDMA)

    5.5.2.3.             18-MC

    5.5.2.4.             Unnamed (DMT)

    5.5.2.5.             Unnamed (LSD, MDMA)

    5.5.3.                Recent Developments and Future Outlook

               

    5.6.                   Janssen Pharmaceuticals

    5.6.1.                Company Overview

    5.6.2.                Financial Information

    5.6.3.                Psychedelic Therapeutics Portfolio

    5.6.3.1.             SPRAVATO®

    5.6.4.                Recent Developments and Future Outlook

     

    5.7.                   Jazz Pharmaceutical

    5.7.1.                Company Overview

    5.7.2.                Financial Information

    5.7.3.                Psychedelic Therapeutics Portfolio

    5.7.3.1.             XYREM®

    5.7.3.2.             JZP-258

    5.7.3.3.             JZP-324

    5.7.4.                Recent Developments and Future Outlook

     

    6.                     CLINICAL TRIAL ANALYSIS

    6.1.                   Chapter Overview

    6.2.                   Scope and Methodology

    6.3.                   Psychedelic Therapeutics: Clinical Trial Analysis

    6.3.1.                Analysis by Trial Registration Year

    6.3.2.                Analysis by Trial Phase

    6.3.3.                Analysis by Trial Recruitment Status

    6.3.4.                Analysis by Trial Registration Year and Number of Patients Enrolled

    6.3.5.                Analysis by Study Design

    6.3.6.                Leading Trial Sponsors: Analysis by Number of Registered Trials

    6.3.7.                Leading Players: Analysis by Number of Registered Trials

    6.3.8.                Analysis by Trial Focus

    6.3.9.                Analysis by Target Therapeutic Area

    6.3.10.              Popular Psychedelic Substance: Analysis by Number of Registered Trials

    6.3.11.              Geographical Analysis by Number of Registered Trials

    6.3.12.             Geographical Analysis by Number of Patients Enrolled

     

     

     

    Contact Information

    Roots Analysis Private Limited

    Gaurav Chaudhary

    +1 (415) 800 3415

    ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis

    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

    Twitter - https://twitter.com/RootsAnalysis